Premium
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
Author(s) -
Volpi Simona,
Bult Carol J.,
Chisholm Rex L.,
Deverka Patricia A.,
Ginsburg Geoffrey S.,
Jacob Howard J.,
Kasapi Melpomeni,
McLeod Howard L.,
Roden Dan M.,
Williams Marc S.,
Green Eric D.,
Rodriguez Laura Lyman,
Aronson Samuel,
Cavallari Larisa H.,
Denny Joshua C.,
Dressler Lynn G.,
Johnson Julie A.,
Klein Teri E.,
Leeder J. Steven,
PiquetteMiller Micheline,
Perera Minoli,
RasmussenTorvik Laura J.,
Rehm Heidi L.,
Ritchie Marylyn D.,
Skaar Todd C.,
Wagle Nikhil,
Weinshilboum Richard,
Weitzel Kristin W.,
Wildin Robert,
Wilson John,
Manolio Teri A.,
Relling Mary V.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1048
Subject(s) - pharmacogenomics , harm , precision medicine , matching (statistics) , medicine , pharmacogenetics , dosing , intensive care medicine , medline , data science , computer science , pharmacology , psychology , biology , pathology , social psychology , biochemistry , genotype , gene
Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.